THE HYPOXIC CELL sensitizer Misonidazole (1 -(2-nitroimidazole-1 -yl)-3-methoxypropan-2-ol, MISO) is currently undergoing worldwide trials of its clinical usefulness. Its primary dose-limiting toxicity is peripheral sensory neuropathy (Wasserman et al., 1979) though encephalopathy is occasional. There is no demonstrable dose threshold for these effects, but the total dose has generally been limited to 12 g/m2 (Dische et al., 1977; Urtasun, 1978) in an attempt to reduce the toxicity to acceptable levels.
There is evidence that the incidence of neurotoxicity is related to the area under the curve (AUC) of plasma drug concentration against time (Dische et al., 1979) or the "exposure index" as defined by Dische, which is the product of the plasma concentration in the plateau period and the half-life. Potentially, a reduction in AUC or "exposure index" might lead to a lower incidence of neurotoxicity. However, since radiosensitization is dependent upon the tumour concentration of MISO at the time of irradiation (McNally et al., 1978; Brown & Yu, 1980) high plasma levels need to be maintained since these and tumour concentration have been shown to be similar in man (Dische et al., 1979; Ash et al., 1979) .
It has already been demonstrated that pre-treatment with phenytoin shortens the half-life of MISO in experimental animals (Workman, 1979; White & Workman, 1980 ) and in patients given 2 large doses of MISO separated by a 14-day course of phenytoin (Workman et al., Accepted 15 June 1981 . This has been explained by phenytoin stimulation of hepatic enzymes concerned wit,h the metabolism of MISO. In one small clinical study, dosing with phenytoin appears to have reduced the neurotoxicity (Wasserman et al., 1980) . This investigation was initiated after a pilot study with MISO in advanced head and neck cancers (Paterson et al., 1981) in which there was a 5500 incidence of peripheral neurotoxicity. Therefore it was decided to examine phenytoin-induced changes in the pharmacokinetics of MISO in 13 patients, 8 with advanced squamous cell carcinoma of the head and neck and 5 with advanced oesophageal tumours. All patients received a conventional daily course of external beam radiotherapy. Seven patients received 0 5 g of MISO on each treatment day, whilst the others received 1 0 g on treatment days 1, 5, 10, 15, 20 and 25. MISO (Roche Products Ltd) was given orally 3 to 4 h before radiation treatment, whilst phenytoin (phenytoin sodium BP) was given orally in a dosage of 100 mg x 3 daily, including weekends, but was started on Day 2 after the initial base-line half-life of MISO had been determined. No patients had abnormal liver function tests. No other drugs known to interfere wit,h MISO metabolism were given, and all patients gave full consent for this investigation.
Blood samples (10 ml) were taken by venepuncture immediately before drug dosage and subsequently at various intervals usually 1, 2, 3-4, 6, 12 and 23 h after MISO dosage. Although 6 samples were normally taken on Day 1, on later occasions only 3-4 samples per patient were taken but these were always those between irradiation time (3-4 h) and before the next dose of MISO (23 h).
Blood samples were placed into lithium heparin tubes and kept in a refrigerator until the plasma was separated by centrifugation and stored in a deep freeze until needed.
Plasma levels of MISO and its metabolite desmethylmisonidazole (DEMIS) were determined by reverse-phase high-performance liquid chromatography (HPLC) using a method similar to Workman et al. (1978) . For drug estimation 0'5 ml plasma was placed in a centrifuge tube with a known quantity of a standard (0.01 ml Ro-07-0913, Roche Products Ltd) and plasma proteins precipitated with 4-5 ml Analar methanol. The clear supernatant after centrifugation was injected into the HPLC (LCUV detector, LCXPS pump and PM 8251 recorder, Pye Unicam Ltd). The separation was on a 10azm Partisil ODS column, the UV spectrophotometer set at 325 nm, the liquid phase was 20% V/V methanol (BDH Chromatographic grade) in distilled water and the flow rate was 2 ml/min. The DEMIS, MISO and standard Ro-07-091 3 appeared as peaks at 135, 268 and 513 sec respectively. The concentration of each compound was determined as the peak height, which was then related to the internal standard Ro-07-091 3.
The Table I . The concentrations of T-NITRO and MISO at the time of irradiation (Table I) throughout radiotherapy do not differ significantly from the concentrations determined on Day 1, and neither radiotherapy nor phenytoin had any effect. The greatest t value is 1P05, with a corresponding P = 0 4. The values in Table I In 5 of the 7 patients who received daily MISO, it was possible to compare T-NITRO levels at 2 h and at the time of irradiation (3-4 h after dosing). On Day 1 the plasma concentration of T-NITRO was 14-0 + 2-4 ,ug/ml at 2 h and 12-8 + 1-6 ,ug/ml at irradiation. By Day 8 these plasma values were 16-4 + 2-9 jug/ml and 13-5 + 2-6 jug/ml respectively, and though the differences are not large they are in agreement with the conclusion of Workman et al. (1978) who also observed higher concentrations at 2 h.
The major dose-limiting toxicity of MISO remains its neurotoxicity, for which the concomitant use of phenytoin has been suggested as a means of reducing this effect (Wasserman et al., 1980; Workman et al., 1980) . This study has demonstrated the time-course of the phenytoin-induced change in the pharmacokinetics of MISO in patients receiving radical radiotherapy, and it has shown that the half-life of both T-NITRO and MISO are significantly reduced by it. Additionally, the plasma concentrations of these drugs at the time of irradiation have not been significantly reduced, suggesting that tumour concentrations and so radiosensitization are not altered. The reduction in the half-life of T-NITRO is interesting in relation to the possible use of DEMIS as a radiosensitizer, though it has recently been shown to produce a similar level of neurotoxicity to MISO in baboons (Lennox-Smith, personal communication) and in man (Dische et al., 1981) . Smith for help with the statistical analysis, and the radiographers at Velindre Hospital, whose support is essential in such clinical investigations.
